Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Equillium, Inc. stock logo
EQ
Equillium
$0.32
+1.7%
$0.38
$0.27
$1.50
$11.07M1.94437,915 shs214,037 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$13.08
+3.1%
$12.51
$5.22
$27.38
$159.74M0.43153,968 shs173,279 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$1.72
-3.4%
$1.68
$1.15
$3.50
$12.45M-0.3722,861 shs6,071 shs
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.39
+6.6%
$0.34
$0.22
$4.19
$15.25M-0.433.13 million shs1.22 million shs
Sio Gene Therapies Inc. stock logo
SIOX
Sio Gene Therapies
$0.48
$0.46
$0.25
$0.50
N/AN/AN/A40,403 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Equillium, Inc. stock logo
EQ
Equillium
0.00%-5.17%-13.86%-20.98%-55.28%
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%+1.28%-1.48%-12.96%+97.66%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
0.00%-0.84%+15.14%+4.71%-44.20%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.00%+9.23%-3.14%-9.23%-91.22%
Sio Gene Therapies Inc. stock logo
SIOX
Sio Gene Therapies
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Equillium, Inc. stock logo
EQ
Equillium
2.399 of 5 stars
3.22.00.00.03.31.70.6
Lifevantage Corporation stock logo
LFVN
Lifevantage
4.029 of 5 stars
3.50.01.72.72.61.71.3
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
4.121 of 5 stars
3.04.00.04.62.20.01.3
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
1.0809 of 5 stars
0.05.00.00.02.70.00.6
Sio Gene Therapies Inc. stock logo
SIOX
Sio Gene Therapies
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Equillium, Inc. stock logo
EQ
Equillium
2.33
Hold$3.00851.78% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50133.18% Upside
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
2.00
Hold$5.00190.70% Upside
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.00
N/AN/AN/A
Sio Gene Therapies Inc. stock logo
SIOX
Sio Gene Therapies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Equillium, Inc. stock logo
EQ
Equillium
$41.10M0.27N/AN/A$0.54 per share0.58
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.82$0.91 per share14.39$2.05 per share6.38
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/A$0.20 per share8.52($3.67) per shareN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$6.77M2.40N/AN/A$0.25 per share1.57
Sio Gene Therapies Inc. stock logo
SIOX
Sio Gene Therapies
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Equillium, Inc. stock logo
EQ
Equillium
-$8.07M-$0.39N/AN/AN/A-19.62%-74.34%-46.75%8/6/2025 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6918.96N/A4.12%34.67%15.24%8/27/2025 (Estimated)
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$1.44M$0.822.10N/AN/AN/A-20.68%15.73%8/5/2025 (Estimated)
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$53.36M-$1.26N/AN/AN/A-217.64%-184.38%-64.59%8/13/2025 (Estimated)
Sio Gene Therapies Inc. stock logo
SIOX
Sio Gene Therapies
-$71.89MN/A0.00N/AN/AN/AN/AN/A

Latest NERV, SIOX, PRPH, LFVN, and EQ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/20/2025Q1 2025
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$0.18-$0.12+$0.06$0.12$2.45 million$1.43 million
5/13/2025Q1 2025
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$1.07-$0.50+$0.57-$0.50N/AN/A
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Equillium, Inc. stock logo
EQ
Equillium
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.38%N/A26.09%3 Years
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
N/AN/AN/AN/AN/A
Sio Gene Therapies Inc. stock logo
SIOX
Sio Gene Therapies
N/AN/AN/AN/AN/A

Latest NERV, SIOX, PRPH, LFVN, and EQ Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Equillium, Inc. stock logo
EQ
Equillium
N/A
2.70
2.70
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/A
9.21
9.21
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.30
1.03
0.98
Sio Gene Therapies Inc. stock logo
SIOX
Sio Gene Therapies
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Equillium, Inc. stock logo
EQ
Equillium
27.05%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
34.56%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.45%
Sio Gene Therapies Inc. stock logo
SIOX
Sio Gene Therapies
N/A

Insider Ownership

CompanyInsider Ownership
Equillium, Inc. stock logo
EQ
Equillium
30.30%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
8.60%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.60%
Sio Gene Therapies Inc. stock logo
SIOX
Sio Gene Therapies
3.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Equillium, Inc. stock logo
EQ
Equillium
4035.72 million24.90 millionNot Optionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
96.99 million6.39 millionNot Optionable
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
13041.54 million37.55 millionOptionable
Sio Gene Therapies Inc. stock logo
SIOX
Sio Gene Therapies
12N/AN/ANo Data

Recent News About These Companies

Sio Gene Therapies Stock Price History
Gene Therapy
Lisa Jarvis: Would you get tested for an Alzheimer’s gene?
Gene therapy and the germline
Gene Therapy for Parkinson's Disease
Sio Gene Therapies Inc SIOX
Two Promising Gene Therapy Stocks Tackling Eye Disease
Gene Therapy News and Research
Gene Therapy for Erectile Dysfunction
In Mice, Gene Therapy Helps Restore Movement After Spinal Cord Injury
Retroviral Vectors for Gene Therapy
Sio Gene Therapies (NASDAQ: AXGT)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Equillium stock logo

Equillium NASDAQ:EQ

$0.32 +0.01 (+1.68%)
As of 04:00 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$13.08 +0.39 (+3.07%)
As of 04:00 PM Eastern

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Minerva Neurosciences stock logo

Minerva Neurosciences NASDAQ:NERV

$1.72 -0.06 (-3.37%)
As of 04:00 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

ProPhase Labs stock logo

ProPhase Labs NASDAQ:PRPH

$0.39 +0.02 (+6.62%)
As of 04:00 PM Eastern

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Sio Gene Therapies stock logo

Sio Gene Therapies NASDAQ:SIOX

Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.